CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 78 enrolled
Drug / intervention
sunitinib malatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00397488
NCT00397488Phase 2Completed
CompareCT.gov

Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium

Memorial Sloan Kettering Cancer Center·interventional·Posted Nov 9, 2006·Updated Jan 25, 2016

In Brief

A Phase 2 clinical trial evaluating sunitinib malate for Bladder Cancer and 2 related conditions. Completed, enrolled 78 participants across 1 site.

Detailed Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with progressive metastatic transitional cell cancer of the urothelium.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Pfizer

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 9, 2006
Enrollment StartSep 1, 2006
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 19.6 years ago

Interventions

sunitinib malatedrug